Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 5;54(1):2213–2221. doi: 10.1080/07853890.2022.2107233

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 1. — Patients with HCC recurrence had advanced tumour characteristics and a higher proportion of preoperative HBV DNA detectable than those with no recurrence. (A) Patients with HCC recurrence had higher AFP concentrations than patients who did not experience recurrence (p<.001). (B) Patients with HCC recurrence had greater tumour numbers compared with patients who did not experience recurrence (p=.034). (C) Patients with HCC recurrence had a longer total tumour diameter than patients without recurrence (p<.001). (D) In patients with HCC recurrence, 54.2% (n = 13) patients had preoperative detectable HBV DNA and 45.8% (n = 11) had undetectable HBV DNA. Patients with HCC recurrence had a higher proportion of preoperative detectable HBV DNA than patients without recurrence (p=.036).